Michael Fort, Chairman of The Concept Life Sciences Group, said the company identified a need for its integrated services in the US market through its existing client base.
“The US is the largest market in the world for pre-clinical services and it was a natural progression for us to offer the whole of our services to this market,” Fort told us.
In fact, as Outsourcing-Pharma.com previously reported, pre-clinical outsourcing is expected to increase 20% this year.
The newly launched US group will offer various chemistry, biology, and analytical services.
Bioconjugates /ADcs, medchem, ADME, synthetic organic chemistry, controlled substances, PR&D, and organic materials, are among the company’s chemistry services.
Additionally, Fort explained that its biology offerings will include investigative and mechanistic toxicology, exploratory and discovery toxicology, metabolism absorption, and PK/TK.
The company’s analytics division also offers pharmaceutical microbiology, stability storage, and other bespoke services.
“We are actively marketing our services in the US with business teams based on the East and West coasts,” said Fort. “For the past 6-9 months we have been soft selling in this territory working with existing clients to refine our offering.”
“We are now more than ready to take that to market and have some very exciting prospects in the pipeline,” Fort added.